Patrick Campbell

The integrated CGM, first cleared over-the-counter for adults in 2024, is now available without a prescription for people 2 years of age and older who do not use insulin.

Phase 3 sunRIZE trial of ersodetug in congenital hyperinsulinism missed its primary endpoint but showed CGM-based glycemic gains.

Two-year CAHtalyst data show crinecerfont sustains androgen reduction and lowers glucocorticoid doses in children with congenital adrenal hyperplasia.

The FDA approved Breztri Aerosphere as the first single-inhaler triple therapy for asthma maintenance in patients 12 years and older.

AbbVie filed an sNDA for upadacitinib to treat severe alopecia areata in adults and adolescents based on phase 3 UP-AA trial results.

FDA clearance is being sought for roflumilast cream for infants 3 months and older with mild to moderate atopic dermatitis.

The FDA approved lunsotogene parvec-cwha as the first gene therapy for genetic hearing loss caused by biallelic OTOF variants.

The FDA approved dupilumab for children aged 2 to 11 years with chronic spontaneous urticaria, making it the first biologic for young pediatric CSU patients.

FDA fully approves sparsentan for FSGS in children 8 years and older, offering the first targeted option and stronger proteinuria drops than irbesartan.

FDA green-lights Imcivree for acquired hypothalamic obesity in patients 4 years and older, delivering major reductions in BMI and hunger in phase 3.

The FDA sanctioned Johnson & Johnson’s once-daily oral pill for adults and adolescents with moderate to severe plaque psoriasis.

A phase 3 trial shows that lebrikizumab improves skin clearance and itch in infants and children with moderate to severe atopic dermatitis.

Secukinumab now treats moderate to severe hidradenitis suppurativa in patients 12 years and older, making it the first IL‑17A biologic option for teens.

FDA okays once-weekly navepegritide for children with achondroplasia, boosting growth with strong trial data; rollout expected early Q2 2026.

The FDA approves recombinant VWF for pediatric von Willebrand disease, enhancing treatment options for children during bleeding episodes and surgeries.

Bobbie expects the launch of their USDA Organic Whole Milk Infant formula to begin in April 2025.

A recap of the FDA submissions and regulatory decisions in pediatrics from January 2025.

The FDA has approved the first generic once-daily GLP-1 injection for the improvement of glycemic control for type 2 diabetes in patients 10 years and up.

A recent study suggests that high ultraprocessed food consumption in preschool children is linked to increased cardiometabolic risk factors.

Viaskin milk patch shows promise in cow’s milk allergy, particularly in children aged 2-11 with 300 μg dose, though the other doses examined failed to prove significant benefit.

Data from a 4-year trial of preschool-aged children offers new insight into the effects of initiating obesity management strategies among children in early life.

An analysis of a nationwide sample of more than 30,000 clinicians provides insight into rates of HPV vaccination among US adolescents and how changes in reimbursement rate might encourage increased vaccination rates.

A follow-up to an earlier study, the latest research leveraged EHR data from medical centers in North Carolina and concluded incident cases of type 1 diabetes increased nearly 50% and incident cases of type 2 diabetes more than doubled in 2021-2022 relative to prepandemic years.

An analysis of data from nearly 750,000 adolescents from more than 40 countries offers insight into the changing, and possibly inaccurate, perceptions of healthy body weight among younger people since the turn of the century.

Results of the study, which was an analysis of accelerometry data the TEDDY study, indicate every 10-minute increase in daily moderate to vigorous physical activity was associated with an 8% reduction in risk of progressing to type 1 diabetes, but this association was not present among those who were single islet autoantibody-positive or single islet autoantibody-negative.

A retrospective analysis of more than 60 patients 21 years or younger who received a transcatheter leadless pacemaker provides an overview of the safety of such an approach in younger patient populations.

The latest scientific statement from the American Heart Association takes aim at offering clinicians with a summary of contemporary evidence related to the prevalence and increase in long-term risk associated with hypertension in children and adolescents.

A study from Slovenia suggests a physical activity intervention that would require physical activity every day while at school was effective for reducing BMI and reversing obesity in young children.

A systematic review and meta-analysis of nearly 3 dozen published articles details the apparent increase in risk of cardiovascular disease and diabetes associated with a diagnosis of autism.

In what investigators are calling the largest study of its kind ever conducted in the US, results of the 2-year study, which included more than 300 transgender or nonbinary youth, underline the positive benefits seen with receipt of gender-affirming hormone therapy among this patient population.